IC
SGMT icon

Ikarian Capital’s Sagimet Biosciences SGMT Stock Holding History

Ikarian Capital’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,984
Closed -$91.3K – 190
2025
Q2 		$91.3K Hold
11,984
– – 0.02% 123
2025
Q1 		$39.1K Hold
11,984
– – ﹤0.01% 156
2024
Q4 		$53.9K Sell
11,984
-375,581
-97% -$1.9M 0.01% 159
2024
Q3 		$1.07M Sell
387,565
-25,000
-6% -$77.1K 0.15% 95
2024
Q2 		$1.41M Hold
412,565
– – 0.25% 62
2024
Q1 		$2.24M Buy
+412,565
New +$2.96M 0.25% 83

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Ikarian Capital's SGMT Position: Q3 2025 in Review

Ikarian Capital sold out of Sagimet Biosciences (SGMT) in Q3 2025, closing a stake of 11,984 shares — an estimated $91.3K sold.

Ikarian Capital first reported a position in SGMT in Q1 2024 and held it in 6 quarters. The position peaked at $2.24M in Q1 2024. 72 funds tracked by Wall St. Rank hold SGMT as of Q3 2025.

  • Ikarian Capital reported no remaining Sagimet Biosciences position as of Q3 2025 after selling out during the quarter.
  • Ikarian Capital sold 11,984 Sagimet Biosciences shares in Q3 2025, an estimated $91.3K.
  • Ikarian Capital first reported a position in Sagimet Biosciences in Q1 2024 and held it in 6 quarters.
  • Ikarian Capital's Sagimet Biosciences position peaked at $2.24M in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.